Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
Kaiser Permanente’s Vaccine Study Center is leading a key part of the national safety surveillance effort for the COVID-19 vaccines, tracking patient data for serious side effects.
Researchers and clinicians with Kaiser Permanente Northern California are developing a wide-ranging research agenda to beat COVID-19, working at the accelerated pace demanded by a worldwide pandemic.
What does it take to be sure the annual flu vaccine is effective and safe? Research. In a podcast, Nicola Klein, head of the Vaccine Study Center, tackles some common questions about the vaccine and recent findings.
People who recovered from active tuberculosis had a higher long-term risk of death from any cause than similar patients who never had active tuberculosis shows a new Kaiser Permanente study.
A Kaiser Permanente analysis of women who did not get flu shots during their pregnancies found the women clustered in geographic “hot spots.” These women tended to have fewer prenatal medical visits and live in low-income neighborhoods.
New research from Kaiser Permanente that followed a large number of people living with HIV over 15 years finds reduced risk of certain cancers is among the benefits of early treatment.
The Division of Research has joined a phase 3 clinical trial testing a Pfizer/BioNTech vaccine against the COVID-19 virus. Kaiser Permanente Southern California and Northwest join them in this global effort.
Kaiser Permanente’s rich history of research and care delivery innovation around HIV and AIDS will be highlighted at the global International AIDS Conference, being held online July 6-10.
Patients reported positive outcomes with use of an HIV prevention medication dosed only as needed, instead of the more common daily dosing, Kaiser Permanente researchers reported.
A JAMA study, using data on patients hospitalized in March from all 21 Kaiser Permanente Northern California hospitals, is one of the first U.S. studies to look at overall hospitalization admissions of COVID-19 patients.